Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KZIA NASDAQ:SPRC NASDAQ:TNFA NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZIANovogen$7.08-4.2%$7.56$2.86▼$39.05$11.68M2.15490,176 shs26,492 shsSPRCSciSparc$4.25-1.4%$3.86$1.75▼$37.59$2.27M1.151.62 million shs102,008 shsTNFATNF Pharmaceuticals$4.52+3.0%$5.53$3.24▼$195.00$8.35M2.043.51 million shs524,452 shsVIVSVivoSim Labs$2.51+1.2%$2.84$1.41▼$21.96$6.53M1.13383,073 shs20,003 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZIANovogen+5.57%+8.52%-4.77%-25.05%-70.58%SPRCSciSparc+12.83%+24.21%-9.64%-47.37%-10.45%TNFATNF Pharmaceuticals0.00%+19.29%+13.73%-58.97%-97.51%VIVSVivoSim Labs-3.13%-16.22%-40.24%+24.62%+247,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKZIANovogen$7.08-4.2%$7.56$2.86▼$39.05$11.68M2.15490,176 shs26,492 shsSPRCSciSparc$4.25-1.4%$3.86$1.75▼$37.59$2.27M1.151.62 million shs102,008 shsTNFATNF Pharmaceuticals$4.52+3.0%$5.53$3.24▼$195.00$8.35M2.043.51 million shs524,452 shsVIVSVivoSim Labs$2.51+1.2%$2.84$1.41▼$21.96$6.53M1.13383,073 shs20,003 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKZIANovogen+5.57%+8.52%-4.77%-25.05%-70.58%SPRCSciSparc+12.83%+24.21%-9.64%-47.37%-10.45%TNFATNF Pharmaceuticals0.00%+19.29%+13.73%-58.97%-97.51%VIVSVivoSim Labs-3.13%-16.22%-40.24%+24.62%+247,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKZIANovogen 2.67Moderate Buy$16.50133.05% UpsideSPRCSciSparc 1.00SellN/AN/ATNFATNF Pharmaceuticals 1.00SellN/AN/AVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SPRC, TNFA, VIVS, and KZIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025KZIANovogenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SPRCSciSparcWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025VIVSVivoSim LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/2/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/27/2025KZIANovogenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SPRCSciSparcWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TNFATNF PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/27/2025VIVSVivoSim LabsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKZIANovogen$1.51M7.74N/AN/A($9.87) per share-0.72SPRCSciSparc$1.31M1.74N/AN/A$18.13 per share0.23TNFATNF PharmaceuticalsN/AN/AN/AN/A$286.76 per shareN/AVIVSVivoSim Labs$140K46.61N/AN/A$5.54 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/A11/21/2025 (Estimated)SPRCSciSparc-$6.28MN/A0.00∞N/AN/AN/AN/AN/ATNFATNF Pharmaceuticals-$23.36M-$231.00N/A∞N/AN/A-69.21%-33.98%11/13/2025 (Estimated)VIVSVivoSim Labs-$2.48M-$10.20N/A∞N/A-1,396.48%-32.95%-21.31%N/ALatest SPRC, TNFA, VIVS, and KZIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025TNFATNF PharmaceuticalsN/A-$18.00N/A-$0.18N/AN/A8/12/2025Q1 2026VIVSVivoSim LabsN/A-$1.14N/A-$1.14N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKZIANovogenN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ATNFATNF PharmaceuticalsN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKZIANovogenN/AN/AN/ASPRCSciSparcN/AN/AN/ATNFATNF PharmaceuticalsN/A0.930.93VIVSVivoSim LabsN/A4.524.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKZIANovogen30.89%SPRCSciSparc25.06%TNFATNF Pharmaceuticals9.64%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipKZIANovogen1.00%SPRCSciSparc1.52%TNFATNF Pharmaceuticals0.45%VIVSVivoSim Labs3.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKZIANovogen121.65 million1.64 millionOptionableSPRCSciSparc4535,000527,000Not OptionableTNFATNF Pharmaceuticals61.85 million1.84 millionN/AVIVSVivoSim Labs202.60 million2.50 millionN/ASPRC, TNFA, VIVS, and KZIA HeadlinesRecent News About These CompaniesVivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Down 68.0% in SeptemberOctober 20 at 2:53 AM | americanbankingnews.comVivoSim Labs Inc (VIVS)October 4, 2025 | investing.comVivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | finanznachrichten.deVivoSim appoints Lialin as Chief Commercial OfficerAugust 14, 2025 | msn.comVivoSim Labs, Inc. Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in 3D Drug Testing ServicesAugust 14, 2025 | quiverquant.comQVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | financialpost.comFVivoSim Labs Appoints Tony Lialin as Chief Commercial OfficerAugust 14, 2025 | globenewswire.comVivoSim: Fiscal Q1 Earnings SnapshotAugust 12, 2025 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRC, TNFA, VIVS, and KZIA Company DescriptionsNovogen NASDAQ:KZIA$7.08 -0.31 (-4.19%) Closing price 03:59 PM EasternExtended Trading$7.08 0.00 (0.00%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.SciSparc NASDAQ:SPRC$4.25 -0.06 (-1.39%) Closing price 04:00 PM EasternExtended Trading$4.16 -0.09 (-2.00%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.TNF Pharmaceuticals NASDAQ:TNFA$4.52 +0.13 (+2.96%) As of 10/20/2025TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.VivoSim Labs NASDAQ:VIVS$2.51 +0.03 (+1.21%) As of 04:00 PM EasternOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
